MAVENCLAD® dosing tool

MAVENCLAD® therapy consists of two treatment courses administered at the beginning of two consecutive years. The course consists of 2 treatment weeks, week 1 and week 5 of the respective year.

Each dose administered is dependent on the individual patient’s body weight.

Based on the weight of the patient and tablets required, more than one script may be required for each treatment week.

MAVENCLAD® is now PBS STREAMLINED Authority listed for eligible patients with relapsing-remitting multiple sclerosis (RRMS)1

Treatment PhaseStreamline Code
Initial treatment10170
Continuing treatment10171
Grandfather treatment10123
Please note the number of tablets taken and the instructions for taking tablets at week 1 differ from week 5.
Please note the number of tablets taken and the instructions for taking tablets at week 1 differ from week 5.
Please note the number of tablets taken and the instructions for taking tablets at week 1 differ from week 5.
Please note the number of tablets taken and the instructions for taking tablets at week 1 differ from week 5.
Please note the number of tablets taken and the instructions for taking tablets at week 1 differ from week 5.

Reference

  1. MAVENCLAD® (cladribine) tablets. PBS Streamlined Authority. Available at: www.pbs.gov.au/browse/streamlined-authority. Accessed March 2020.